Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair

AI-generated analysis

πŸš€ FDA grants 510(k) clearance to Philips' new EchoNavigator R5.0 software with DeviceGuide AI solution.

❀️ This technology provides real-time guidance for repairing leaking mitral valves via minimally invasive catheter-based approaches.

🀝 The AI tool was developed in collaboration with Edwards Lifesciences, combining imaging expertise with valvular therapy development.

🌍 Mitral regurgitation affects over 35 million adults globally and more than 2 million in the United States alone.

πŸ’‘ DeviceGuide fuses live echocardiography images from Philips EPIQ CVxi with X-ray images from the Azurion system into one view.

🧠 The AI algorithm automatically tracks and visualizes the Edwards PASCAL Ace mitral valve repair device during surgery.

πŸ‘¨β€βš•οΈ Dr. Atul Gupta states the AI acts as an assistive tool that amplifies physician expertise rather than replacing it.

πŸ₯ Investigators worked closely with sites in Europe and the U.S., including Columbia University Irving Medical Center.

🎯 Dr. Susheel Kumar Kodali notes the software provides visual overlays and trajectory lines to simplify device positioning.

πŸ” The system continuously informs interventionalists about the device's location in space relative to the heart valve anatomy.

⚑ This integrated workflow helps physicians manage complexity, improve precision, and treat more patients safely during beating heart procedures.

πŸ”— DeviceGuide is part of Philips' broader connected cardiology ecosystem supporting patient care from diagnosis through recovery.

πŸ“… The technology will be showcased at the American College of Cardiology (ACC) 2026 meeting in New Orleans.

🧩 M-TEER procedures require experienced teams to coordinate movements and interpret multiple screens for accurate device placement.

🎨 DeviceGuide combines imaging, real-time data, and intelligent software within a unified workflow for more consistent results.

⚠️ The AI minimizes unnecessary repositioning of the imaging window and streamlines procedural guidance for better team coordination.

πŸ“ˆ Structural heart procedures are among the fastest-growing areas in cardiology but also some of the most technically demanding.

🎯 Mark Stoffels highlights that the shared view improves team communication and gives the entire procedure room a clearer picture.

πŸ”’ Physician control remains with the operator, ensuring safety and confidence while navigating complex intracardiac anatomy.

πŸ’» The solution supports Edwards Lifesciences' M-TEER workflow to make these procedures more intuitive and streamlined for clinicians.

πŸ‡³πŸ‡± Philips is a global leader in health technology based in Amsterdam with headquarters listed on NYSE and AEX exchanges.

Bullish Signals
  • Royal Philips announced receipt of U.S. FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, validating its AI-powered solution for assisting physicians during minimally invasive mitral valve repair procedures.
  • The FDA-cleared software integrates with the Philips Azurion image-guided therapy platform to combine live echocardiography and X-ray images into a single, unified workflow for consistent and efficient procedures.
  • DeviceGuide was developed in close collaboration with Edwards Lifesciences, aligning both companies' expertise to streamline complex mitral transcatheter edge-to-edge repair (M-TEER) workflows.
  • The solution helps clinicians navigate and position the Edwards PASCAL Ace mitral valve repair device with greater clarity and confidence during procedures involving over 35 million adults worldwide affected by mitral regurgitation.
  • By automating tracking and visualization of the repair device, DeviceGuide minimizes unnecessary repositioning of the imaging window and may improve the precision of device implantation.
  • The AI software serves as an assistive tool rather than a replacement for physician expertise, giving doctors an extra pair of eyes to treat more patients safely and confidently.
  • DeviceGuide will be showcased at the American College of Cardiology (ACC) 2026 meeting in New Orleans, highlighting its position at a leading forum for cardiovascular innovation.
  • According to Dr. Susheel Kumar Kodali from NewYork-Presbyterian/Columbia University Irving Medical Center, DeviceGuide simplifies the procedure and improves team communication by providing a single, intuitive presentation of real-time target and orientation.
  • Mark Stoffels at Philips noted that structural heart procedures are among the fastest-growing areas in cardiology, positioning this innovation to help manage complexity and increase procedural confidence.
Risk Factors
  • The article contains no negative aspects or risks to summarize as it is an exclusively positive news release about FDA clearance and new product launches, with no mention of declining metrics, regulatory hurdles, financial concerns, or competitive threats.
Full Analysis
Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an artificial intelligence-powered software solution designed to assist physicians during minimally invasive mitral valve repair procedures. Developed in collaboration with Edwards Lifesciences, the technology integrates with the Philips Azurion image-guided therapy platform to combine imaging, real-time data, and intelligent software into a unified workflow. The AI algorithm automatically tracks and visualizes the Edwards PASCAL Ace mitral valve repair device by fusing live echocardiography images from the Philips EPIQ CVxi cardiovascular platform with live X-ray images from the Azurion system. This integration creates a single, integrated view that helps clinicians navigate and position the device with greater clarity and confidence during one of interventional cardiology's most technically demanding procedures. Mitral regurgitation affects more than 35 million adults worldwide and over 2 million in the United States, prompting the need for alternatives to open heart surgery such as mitral transcatheter edge-to-edge repair (M-TEER). During these complex M-TEER procedures, physicians make a small skin incision to access a vein, allowing catheters to reach the heart where they must position a device delivery system and guide its placement into the diseased mitral valve. The process requires experienced physicians to interpret X-ray and ultrasound images on multiple screens while coordinating movements between operators, making precise adjustments to grasp moving valve leaflets and confirming results in real time. DeviceGuide addresses these challenges by providing an assistive tool that acts as an extra pair of eyes for the medical team without replacing physician expertise. The software's AI automatically aligns imaging to the device in real time, continuously informing the interventionalist about the location of the device within space on the imaging screen. Dr. Atul Gupta, Chief Medical Officer Diagnosis & Treatment at Philips, emphasized that the technology gives physicians an extra pair of eyes to help them treat more patients safely and confidently, ensuring the physician always remains in control. Leading cardiac professionals involved in the development include Susheel Kumar Kodali, MD, director of the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Irving Medical Center, who noted that the visual overlay and trajectory lines simplify the procedure and improve team communication. Additionally, Rebecca T. Hahn, MD, director of interventional echocardiography, stated that the AI minimizes unnecessary repositioning of the imaging window and may improve the precision of device implantation by streamlining procedural guidance. DeviceGuide will be showcased at the American College of Cardiology (ACC) 2026 meeting in New Orleans as part of Philips' connected cardiology ecosystem aimed at helping physicians care for heart patients from diagnosis through recovery. Mark Stoffels, Business Leader of Image Guided Therapy Systems at Philips, described the technology as a step toward handling the complexity of structural heart procedures among the fastest-growing areas in cardiology. By assisting physicians with real-time visualization and navigation inside the beating heart, the solution aims to help teams manage procedure complexity and perform operations more confidently, ultimately supporting the goal to treat more patients effectively through improved coordination and shared views within the catheterization laboratory workflow.